logo-loader
viewFutura Medical PLC

Futura Medical trial on track to deliver “major value inflection point”

The first of two phase III studies of MED2005 got underway in October, treating 1,000 men at 60 centres across Europe

blue pills
The company has developed a fast-acting gel for erectile dysfunction, which will be used to treat men who can take the little blue pill

Futura Medical PLC (LON:FUM) confirmed it will deliver the results from its phase III trial for a fast-acting gel for erectile dysfunction (ED) by the end of the year, a milestone which expects to be a “major value inflection point”.

The first of two studies of MED2005 got underway in October treating 1,000 men at 60 centres across Europe. Headline data should be released towards the back-end of 2019, the company said.

WATCH: Futura Medical fully funded and on track with critical erectile dysfunction trial

Planning for a second, confirmatory final-phase analysis has been undertaken after “extensive dialogue" with regulators and opinion leaders, investors were told.

It will incorporate a US patient group, which is expected to allow Futura to make a regulatory filing in the US. It said “discussions continue” with potential commercial partners, though nothing is likely to be concluded until it has the phase III trial results are public.

Prelims

The update came alongside prelims from the healthcare business, which sharpened its focus last year to concentrate on two potential big sellers - MED2005, the ED treatment, and TPR100, a topical non-steroidal anti-inflammatory and pain killer.

Thornton & Ross, a subsidiary of German pharma STADA, is seeking UK marketing approval for the latter. In its update, Futura said it is in “ongoing discussions” with several other potential distribution partners, but added: “Any further licensing deals are expected to be after UK regulatory approval.”

Turning to the financials, the business posted a £5.89mln loss for the year ended December 31. More importantly, having raised £5.85mln last November (and with cash resources of £9.16mln at the year-end), it has the financial runway to see it through to the data readout for its ED breakthrough.  

Quick facts: Futura Medical PLC

Price: 34.5 GBX

AIM:FUM
Market: AIM
Market Cap: £70.61 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Futura Medical PLC named herein, including the promotion by the Company of Futura Medical PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: Block Energy completes critical phase of WR-38Z sidetrack

Headlines from Proactive UK newsroom. Block Energy (LON:BLOE) has completed a critical phase of the sidetrack programme at its WR-38Z well on the West Rustavi field in Georgia. New casing has been cemented through the build section of the well, which will prevent fluid incursion into the...

4 weeks, 1 day ago

2 min read